AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02588677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00660647
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline injection 0.9%, 0.8 ml s.c. every second week up to 2 years
Trial: NCT01214226
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prolonged-release tablets 3 time per day for 1 month
Trial: NCT02359305
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen given by IV
Trial: NCT02359305
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen suppository given rectally
Trial: NCT01233505
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03428022
Drug: Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
Trial: NCT00211848
Drug: Polyenylphosphatidylcholine (PPC)
RxNorm normalized name: lysophosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06309732
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Doses are titrated against renal function. Dosage: 30 mins loading plus 12 hour infusion
Trial: NCT01221792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non active comparator
Trial: NCT01864655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given to placebo group
Trial: NCT04292483
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled vasodilator to increase pulmonary capillary perfusion
Trial: NCT00229593
Drug: Testosterone Gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg Testosterone gel daily for 3 weeks
Trial: NCT00025363
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00025363
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00334958
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 placebo tablets twice daily.
Trial: NCT03773263
Drug: sequential IVM system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The immature oocytes will be cultured in sequential oocyte IVM medium 1 for 6 hours (37℃, 5% CO2). After flushed 3 times, COCs were removed into sequential oocyte IVM medium 2 for further cultivation.
Trial: NCT01389388
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All the patients who have signed the informed consent will after they have had performed a MCT and possibly SCC with an IVUS, will be give Rosuvastatinuntill their LDL level has reached 1.6-1.8 mmol/l. The objective is that all the participants should have reached 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
Trial: NCT04350580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium chloride 0.9% in the same volume and over the same time as the immunoglobulin
Trial: NCT03716427
Drug: CT1812
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00048126
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg po bid
Trial: NCT02567968
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg). The time to wake will be measured.
Trial: NCT02567968
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthetized volunteers will be allowed to wake after injection of saline (placebo control). The time to wake will be measured.
Trial: NCT01924078
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: metronomic use: capecitabine 500mg/tid
Trial: NCT01533077
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of BIA 9-1067 (single-dose)
Trial: NCT01533077
Drug: Sinemet® 100/25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immediate-release levodopa/carbidopa 100/25 (single-dose).
Trial: NCT01924078
Drug: aromatase Inhibitors (AIs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.
Trial: NCT02702817
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pale blue oval tablets
Trial: NCT00167648
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol patches, six at 0.1 mg each, changed every 3-4 days
Trial: NCT02702817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pale blue oval tablets with no active ingredients, identical in appearance to naproxen intervention
Trial: NCT00807170
Drug: ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg as a once daily oral dose, 21 days
Trial: NCT00807170
Drug: ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg as a once daily oral dose, 21 days
Trial: NCT00376337
Drug: Systemic antifungal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT01395030
Drug: 18F-fluoromethylcholine
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo FCH PET/CT
Trial: NCT03574857
Drug: Chlorothiazide Injection
RxNorm normalized name: chlorothiazide Injection
DrugBank: Chlorothiazide (DB00880)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1: Chlorothiazide 500 mg IV Day 2: Chlorothiazide 500 mg IV
Trial: NCT02079766
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 370 megabecquerel (MBq) IV single-dose
Trial: NCT00113022
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive equivalent of 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
Trial: NCT01355081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine placebo
Trial: NCT03629249
Drug: Placebo once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 150 mg and one tablet blinded placebo to QAW039 450 mg).
Trial: NCT03629249
Drug: QAW039 150 mg once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAW039 150 mg once daily (one tablet of blinded QAW039 150 mg to be given together with one tablet blinded placebo to QAW039 450 mg)
Trial: NCT03629249
Drug: QAW039 450 mg once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAW039 450 mg once daily (one tablet of blinded QAW039 450 mg to be given together with one tablet blinded placebo to QAW039 150 mg)
Trial: NCT00276757
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00276757
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00276757
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03096821
Drug: ngFDS selected treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment based on next-generation functional drug screening (ngFDS). Treatment with commercially available treatments (per package insert instructions) selected by functional drug screening. For drug screening tumor cells from bone marrow aspirates, peripheral blood, pleural effusion, or excised lymph node samples are purified over Ficoll gradient (bone marrow, peripheral blood, pleural effusion) (GE healthcare) or homogenized and filtered (lymph tissue).
Trial: NCT01597401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.
Trial: NCT01938482
Drug: 0.3% GSK1940029 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be supplied as gel for topical application
Trial: NCT01938482
Drug: 1% GSK1940029 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be supplied as gel for topical application
Trial: NCT01938482
Drug: 0.3%/1% vehicle gel only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be supplied as gel for topical application
Trial: NCT01790568
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01621165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
Trial: NCT05086848
Drug: Irinotecan liposome、5-fluorouracil、Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan liposome、5-fluorouracil、Leucovorin
Trial: NCT00545402
Drug: Mycophenolate mofetil, adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d PO BID during meals from Day 0 to Day 4, followed by dose adjustment based on AUC using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12.
Trial: NCT03095222
Drug: Opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care for pain management.
Trial: NCT00545402
Drug: Corticosteroids, IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-15 mg/kg IV pre-operation on Day 0
Trial: NCT00545402
Drug: Mycophenolate mofetil, Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/d PO BID during meals from Day 0 to Month 12
Trial: NCT00545402
Drug: Corticosteroids, PO
RxNorm normalized name: Corticosteroids, potent (group III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d QDS from Day 0 through Month 1; 15 mg/day, TID from the end of Month 1 through Month 2; 10 mg/d BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
Trial: NCT01806805
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00074854
Drug: CP-547,632
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01624259
Drug: LY2189265
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02237781
Drug: Gonadotropins
RxNorm normalized name: GONADOTROPINS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH will depend on the levels of E2 and FSH prior to ovarian stimulation .
Trial: NCT00314353
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 850 mg/m2 po BID Days 1-14 every 21 days for eight cycles\*#~\*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.~#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID
Trial: NCT01362361
Drug: mFOLFOX6 + BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 + BIBF1120 (2x200 mg/d d1-d14) (repeated every 14 days)
Trial: NCT01362361
Drug: mFOLFOX6+placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 + placebo (2x200 mg/d d1-d14) (repeated every 14 days)
Trial: NCT00577109
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/m2 iv on day 1 of each 2 week cycle
Trial: NCT00577109
Drug: 5 FU
RxNorm normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg/m2 iv on day 1 of each 2 week cycle
Trial: NCT02726971
Drug: Femoston
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.
Trial: NCT03255148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray
Trial: NCT00145522
Drug: 17ß-Estradiol/Dydrogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/5 mg/day for 12 cycles of 28 days
Trial: NCT03372850
Drug: HIP1601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test Drug
Trial: NCT03372850
Drug: HGP1705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Drug
Trial: NCT04076254
Drug: Albumins
RxNorm normalized name: lactalbumins, hydrolyzates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albumin 5%
Trial: NCT03555916
Drug: BOTOX®, Allergan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 U BTX-A (BOTOX®, Allergan) powder diluted in 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
Trial: NCT03555916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
Trial: NCT01817907
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a sugar pill during the placebo arm
Trial: NCT03420079
Drug: FCN-411 Dose-escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~* FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR.
Trial: NCT02465983
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single dose of chemotherapy to be administered prior to dosing of the CART-meso-19 cells
Trial: NCT02216071
Drug: EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension
RxNorm normalized name: Otocort Sterile Suspension Otic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
Trial: NCT03161288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT01817283
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills produced the same as Triptolide wilfordii.
Trial: NCT00622284
Drug: Placebo identical to BI 1356 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily
Trial: NCT01717287
Drug: Other Anti-Retroviral Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing
Trial: NCT02242201
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection, weight-based dosage of 100 mcg - 300 mcg
Trial: NCT02242201
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection, 30 mg
Trial: NCT00556127
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg/m2 on day 3
Trial: NCT00282984
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg placebo twice daily by mouth for 12 weeks
Trial: NCT01587378
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical placebo tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
Trial: NCT02146742
Drug: ASP1707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02146742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00912353
Drug: AZD7268
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Oral
Trial: NCT00912353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Oral
Trial: NCT00190671
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
Trial: NCT04205201
Drug: Drugs, Investigational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To see the safety and efficacy of topical latanoprost compared with topical brimonidine in the treatment of the primary open angle
Trial: NCT00454896
Drug: VESIcare®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00454896
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03926130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03926130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03583333
Drug: IMI/REL FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Imipenem, 500 mg Cilastatin and 250 mg Relebactam powder FDC provided in a single vial
Trial: NCT03583333
Drug: PIP/TAZ FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 mg Piperacillin and 500 mg Tazobactam powder FDC provided in a single vial
Trial: NCT01513070
Drug: Quick-Acting Heart Reliever
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quick-Acting Heart Reliever，200mg，tid，po. for six months
Trial: NCT01187966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01636570
Drug: Placebo Comparator: Sugar Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.
Trial: NCT00307645
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00245544
Drug: MK0759
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04910230
Drug: nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In addition to usual care, the treatment group was given 500mg nicotinamide daily, divided into 5 doses
Trial: NCT00307645
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01738542
Drug: Antiaggregant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAS 100mg/d or Clopidogrel 75mg/d
Trial: NCT03252938
Drug: IMP321
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
Trial: NCT01738542
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01244126
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2mcg/kg fentanyl IN
Trial: NCT03596372
Drug: BAY1834942
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation:~Sequential dose levels~.~Dose expansion (except for low-dose expansion):~With maximum tolerated dose (MTD) identified in dose escalation part.
Trial: NCT03420014
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).